Commercial biotechnology in Germany has taken off during the past decade, but creating a viable sector may require a change in strategy in the future.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Müller, C. The evolution of the biotechnology industry in Germany. Trends Biotechnol. In press, July, 2002
Sontheimer, G. & Matzen, T.J.C. Venture Capital-Finanzierung, in Herstatt, C. & Müller, C. Management-Handbuch Biotechnologie (Schäffer-Poeschel, Stuttgart; 2002)).
The Boston Consulting Group. Positionierung deutscher Biotechnologie-Cluster im internationalen Vergleich (January 2001).
Herstatt, C. & Müller, C. Management-Handbuch Biotechnologie (Schäffer-Poeschel, Stuttgart; 2002).
Fletcher, L. Nat. Biotechnol. 20, 211 (2002).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Müller, C., Rump, A. Time for consolidation in Germany. Nat Biotechnol 20, 441–444 (2002). https://doi.org/10.1038/nbt0502-441
Issue Date:
DOI: https://doi.org/10.1038/nbt0502-441
This article is cited by
-
Strategic rethink for German biotechnology
Nature Biotechnology (2002)